FDA panel to discuss Roche arthritis drug July 29

LONDON, June 5 (Reuters) - Roche Holding AG's (ROG.VX) experimental arthritis drug Actemra will be considered for approval by a U.S. Food and Drug Administration panel on July 29.

The new drug, which Roche views as a potential blockbuster, will be discussed by the watchdog's Arthritis Advisory Committee, according to the agency's telephone information line. (Reporting by Ben Hirschler)